How does A170900's PS Ratio compare to its peers?

A170900 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2x).

How does A170900's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

A170900 is expensive based on its Price-To-Sales Ratio (0.8x) compared to the KR Pharmaceuticals industry average (0.8x).

What is A170900's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A170900 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

What is the Fair Price of A170900 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A170900 (₩61700) is trading below our estimate of [[fair value]] (₩293708.04)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Dong-A ST (KOSE:A170900) - Stock Price, News & Analysis

A170900 Stock Overview

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally. More details

A170900 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 79% below our estimate of its fair value

Earnings are forecast to grow 65.52% per year

Analysts in good agreement that stock price will rise by 48.6%

Risk Analysis

Shareholders have been diluted in the past year

Dong-A ST Co., Ltd. Competitors

BINEX

KOSDAQ:A053030

₩517.8b

Shinpoong PharmaceuticalLtd

KOSE:A019170

₩577.5b

JW Pharmaceutical

KOSE:A001060

₩591.4b

Dong-A Socio Holdings

KOSE:A000640

₩674.5b

Price History & Performance

Summary of all time highs, changes and price drops for Dong-A ST
Historical stock prices
Current Share Price	₩61,700.00
52 Week High	₩88,000.00
52 Week Low	₩56,078.43
Beta	0.60
11 Month Change	-17.84%
3 Month Change	-18.71%
1 Year Change	7.95%
33 Year Change	-10.09%
5 Year Change	-40.84%
Change since IPO	-56.77%

Is Dong-A ST (KRX:170900) A Risky Investment?

Oct 16

Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Aug 21

Recent updates

Is Dong-A ST (KRX:170900) A Risky Investment?

Oct 16

Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Aug 21

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 25

Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 07

Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Feb 09

Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Jan 25

Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Jan 11

Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dec 25

Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Dec 22

Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

Dec 07

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Nov 19

Shareholder Returns

	A170900	KR Pharmaceuticals	KR Market
7D	-9.7%	-3.1%	2.9%
1Y	7.9%	4.8%	-2.8%

Return vs Industry: A170900 exceeded the KR Pharmaceuticals industry which returned 4.8% over the past year.

Return vs Market: A170900 exceeded the KR Market which returned -2.8% over the past year.

Price Volatility

Is A170900's price volatile compared to industry and market?
A170900 volatility
A170900 Average Weekly Movement	5.3%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A170900 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A170900's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1932	1,687	n/a	www.donga-st.com

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj.

Dong-A ST Co., Ltd. Fundamentals Summary

How do Dong-A ST's earnings and revenue compare to its market cap?
A170900 fundamental statistics
Market cap	₩554.01b
Earnings (TTM)	-₩6.68b
Revenue (TTM)	₩675.41b

0.8x

P/S Ratio

-83.0x

P/E Ratio

Is A170900 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A170900 income statement (TTM)
Revenue	₩675.41b
Cost of Revenue	₩344.12b
Gross Profit	₩331.28b
Other Expenses	₩337.96b
Earnings	-₩6.68b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-743.77
Gross Margin	49.05%
Net Profit Margin	-0.99%
Debt/Equity Ratio	86.8%

How did A170900 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

-62%

Payout Ratio

A170900 Stock Overview

Rewards

Risk Analysis

Dong-A ST Co., Ltd. Competitors

KOSDAQ:A053030

₩517.8b

KOSE:A019170

₩577.5b

KOSE:A001060

₩591.4b

KOSE:A000640

₩674.5b

Price History & Performance

Recent News & Updates

Dong-A ST Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Is Dong-A ST (KRX:170900) A Risky Investment?

US FDA Approves Dong-A ST's Imuldosa (ustekinumab-Sslf), a Biosimilar to Stelara

New minor risk - Shareholder dilution

Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Dong-A ST Co., Ltd. to Report First Half, 2024 Results on Jul 25, 2024

Recent updates

Dong-A ST Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Is Dong-A ST (KRX:170900) A Risky Investment?

US FDA Approves Dong-A ST's Imuldosa (ustekinumab-Sslf), a Biosimilar to Stelara

New minor risk - Shareholder dilution

Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking

Dong-A ST Co., Ltd. to Report First Half, 2024 Results on Jul 25, 2024

Price target increased by 8.5% to ₩84,247

Less than half of directors are independent

Dong-A ST Co., Ltd. to Report Q1, 2024 Results on May 02, 2024

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: ₩1,311 (vs ₩1,606 in FY 2022)

Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Dong-A ST Co., Ltd., Annual General Meeting, Mar 26, 2024

Dong-A ST Co., Ltd., Annual General Meeting, Mar 26, 2024

Price target increased by 7.6% to ₩77,624

Now 22% overvalued after recent price rise

Dong-A ST Co., Ltd. to Report Fiscal Year 2023 Results on Feb 15, 2024

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara

Upcoming dividend of ₩686 per share at 1.1% yield

New minor risk - Profit margin trend

Investor sentiment improves as stock rises 21%

New minor risk - Share price stability

Investor sentiment improves as stock rises 28%

Dong-A ST Co., Ltd. to Report Q2, 2023 Results on Jul 27, 2023

Now 21% undervalued after recent price drop

EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar

Full year 2022 earnings released: EPS: ₩1,606 (vs ₩1,519 in FY 2021)

Dong-A ST Co., Ltd. Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III

Upcoming dividend of ₩1,000 per share

High number of new directors

Price target decreased to ₩77,200

Price target decreased to ₩95,667

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of ₩1,000 per share

Price target decreased to ₩105,000

Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?

Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit

Full year 2020 earnings released: EPS ₩3,212 (vs ₩8,404 in FY 2019)

A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)

Dong-A ST Co., Ltd., Annual General Meeting, Mar 24, 2021

New 90-day low: ₩82,100

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Dong-A ST Co., Ltd. Completes the Proof-Of-Concept Study for ‘DA-1241,’ an Investigational First-In-Class Small Molecule with Mechanism of GPR119 Agonist Under Clinical Development, in Patients with Type 2 Diabetes

Dong-A ST Co., Ltd. to Report Fiscal Year 2020 Results on Feb 03, 2021

New 90-day low: ₩82,500

Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Upcoming Dividend of ₩1,000 Per Share

New 90-day low: ₩83,800

Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

A Look At Dong-A ST's (KRX:170900) Share Price Returns

New 90-day low: ₩85,000

New 90-day high - ₩104,500

Dong-A ST Co., Ltd. to Report First Half, 2020 Results on Jul 29, 2020

Shareholder Returns